Skip to main content
. 2021 Jan 11;5(1):262–273. doi: 10.1182/bloodadvances.2020002185

Figure 3.

Figure 3.

aGVHD II-IV. (A) We observed a tendency towards less aGVHD in patients having MSD (P = .071). (B) Patients receiving allo-HSCT during infancy (<13 months) suffered significanlty less aGVHD than older patients (P = .008). (C) A matched CMV serostatus correlated to less aGVHD (P = .018). (D) Predicted OS in patients according to patients’ aGVHD at day 30. The survival probability of OS was significatly reduced in patients developing aGVHD II-IV by day 30 (HR = 3.6 [95% CI 1.43-9.14]; P = .006).